Evidence map›Paper›PMID 39165490›Full record

ArticleTransplantation direct2024

Pediatric Combined Heart-liver Transplantation: A Single-center Long-term Experience.

Steven Levitte, Riya Nilkant, Sharon Chen, Angela Beadles, Joanne Lee, Clark A Bonham, David Rosenthal, Amy Gallo, Seth Hollander, Carlos Esquivel and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation direct, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Steven LevitteDivision of Pediatric Gastroenterology, Hepatology, and Nutrition, Stanford University, Palo Alto, CA.ORCID https://orcid.org/0000-0002-3324-5464
Riya NilkantDepartment of Cardiothoracic Surgery, Stanford University, Palo Alto, CA.
Sharon ChenDivision of Pediatric Cardiology, Stanford University, Palo Alto, CA.
Angela BeadlesDepartment of Pharmacy, Lucile Packard Children's Hospital, Palo Alto, CA.
Joanne LeeDepartment of Pharmacy, Lucile Packard Children's Hospital, Palo Alto, CA.
Clark A BonhamDivision of Abdominal Transplantation, Department of Surgery, Stanford University, Palo Alto, CA.
David RosenthalDivision of Pediatric Cardiology, Stanford University, Palo Alto, CA.
Amy GalloDivision of Abdominal Transplantation, Department of Surgery, Stanford University, Palo Alto, CA.
Seth HollanderDivision of Pediatric Cardiology, Stanford University, Palo Alto, CA.
Carlos EsquivelDivision of Abdominal Transplantation, Department of Surgery, Stanford University, Palo Alto, CA.
Michael MaDepartment of Cardiothoracic Surgery, Stanford University, Palo Alto, CA.
Ke-You ZhangDivision of Pediatric Gastroenterology, Hepatology, and Nutrition, Stanford University, Palo Alto, CA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Combined heart liver transplant (CHLT) continues to gain attention as a surgical treatment for patients with end-stage heart and liver disease but remains rare. We present our institutional longitudinal experience with up to 14 y of follow-up, focused on long-term outcomes in CHLT recipients. Methods: We conducted a single-institutional, retrospective review from January 1, 2010, to December 31, 2023, including 7 patients ages 7-17 y who underwent CHLT. Results: Most patients were surgically palliated via Fontan procedure pretransplant (n = 6), and all had evidence of advanced fibrosis or cirrhosis before transplant. The 30-d mortality was 14.3% (n = 1, multiorgan failure). During the follow-up period, 1 patient developed acute heart rejection which required treatment and 2 developed acute liver rejection. In all cases, rejection was successfully treated. Two patients developed acute heart rejection which did not require treatment (grade 1R). No patients developed chronic or refractory rejection. No patients developed allograft coronary artery vasculopathy. Conclusions: CHLT remains a rarely performed treatment for pediatric patients with end-stage heart and liver disease, but our long-term data suggest that this treatment strategy should be considered more frequently.

Identifiers

PMID39165490
PMCPMC11335332

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.